SCHEMBL2797240

SCHEMBL2797240

COc1ccc([C@H]2CNC(=O)[C@H](Cc3ccc(F)c(F)c3)C2)cc1OC1CCCC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 14/20 0.75
PDE4B Q07343 16/20 0.56
PDE4A P27815 14/20 0.56
PDE4C Q08493 12/20 0.56
CYP3A4 P08684 2/20 0.56
VEGFA P15692 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
MAPT P10636 1/20 0.56
CYP2C9 P11712 1/20 0.56
ALOX15 P16050 1/20 0.56
CREBBP Q92793 1/20 0.56
KDM4E B2RXH2 1/20 0.56
PDE5A O76074 1/20 0.56
TNF P01375 1/20 0.56
MAPK1 P28482 1/20 0.56
BLM P54132 1/20 0.56
PDE1A P54750 1/20 0.56
PDE1B Q01064 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2800773 1.00 PDE4D (0.75) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL4439826 1.00 PDE4D (0.75) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL2800658 0.91 PDE4D (0.74) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL2797304 0.91 PDE4D (0.74) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL4446949 0.91 PDE4D (0.74) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL2799165 0.91 PDE4D (0.80) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL2798550 0.90 PDE4D (0.78) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL2797236 0.89 PDE4D (0.74) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL2800081 0.88 PDE4D (0.82) PDE4DPDE4BPDE4APDE4CCYP3A4
SCHEMBL4443655 0.88 PDE4D (0.81) PDE4DPDE4BPDE4APDE4CCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551805-B1 SUBSTITUTED GAMMA-PHENYL-DELTA-LACTAMS AND USES RELATED THERETO DART NEUROSCIENCE CAYMAN LTD (KY) 2013-04-03 EP disclosed
US-20100168170-A1 Piperidinones Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2010-07-01 US disclosed
EP-2137150-A1 PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2009-12-30 EP disclosed
WO-2008110794-A1 PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168170-A1 Piperidinones Useful in the Treatment of Inflammation ARG1, ARG2, PRMT1 PDE4D 1120/4885PDE4B 771/4885PDE4A 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.